Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)
You may also be interested in...
On Heels of Remsima Launch, Celltrion Gears Up For Herceptin Biosimilar Approval In Korea
Following the start of sales of Remsima, a biosimilar of J&J’s Remicade, Celltrion is moving to begin selling its Herceptin biosimilar in Korea this year. It will be Celltron’s second biosimilar on the market.
Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year
Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year